Regulation & law · 30/12/2002
VaxGen, Inc. to Receive Exclusive License for Anthrax Vaccine Patent
The U.S. government has announced its intent to grant an exclusive, royalty-bearing license to VaxGen, Inc. for two patents related to anthrax vaccine development, with the license set to be used for preventive vaccines against anthrax infection.
Original source language: Federal Register — All DocumentsOpen original release →